Incidence and risk factors for low trauma fractures in men with prostate cancer

Bone

Volumn 43, Issue 3, 2008, Pages 556-560

  Ahlborg, Henrik G ^a,b   Nguyen, Nguyen D ^a   Center, Jacqueline R ^a   Eisman, John A ^a,c   Nguyen, Tuan V ^a,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Bone mineral density; Fracture; Men; Osteoporosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; GOSERELIN;

ADULT; AGED; ARTICLE; BODY POSTURE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMUR NECK; FOLLOW UP; FRACTURE; HUMAN; INJURY SEVERITY; LIFESTYLE; LUMBAR SPINE; MALE; MORBIDITY; OSTEOLYSIS; OSTEOPOROSIS; POPULATION BASED CASE CONTROL STUDY; PROSTATE CANCER; RISK FACTOR;

AGE FACTORS; AGED; BONE DENSITY; FRACTURES, BONE; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; RISK FACTORS;

EID: 49149088041     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.05.003     Document Type: Article

References (40)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics, 2001. CA Cancer J Clin 51 (2001) 15-36
2. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
3. Wasson J.H., Fowler Jr. F.J., and Barry M.J. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol 159 (1998) 1993-1996 discussion 1996-7
4. Seeman E., Young N., Szmukler G., Tsalamandris C., and Hopper J.L. Risk factors for osteoporosis. Osteoporos Int 3 Suppl 1 (1993) 40-43
5. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., and Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 (1999) 1219-1222
6. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181-186
7. Stoch S.A., Parker R.A., Chen L., Bubley G., Ko Y.J., Vincelette A., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86 (2001) 2787-2791
8. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Faerber G.J., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607-611
9. Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361-2367 discussion 2367
10. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439-444
11. Townsend M.F., Sanders W.H., Northway R.O., and Graham Jr. S.D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79 (1997) 545-550
12. Hatano T., Oishi Y., Furuta A., Iwamuro S., and Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86 (2000) 449-452
13. Oefelein M.G., Ricchuiti V., Conrad W., Seftel A., Bodner D., Goldman H., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166 (2001) 1724-1728
14. Diamond T.H., Bucci J., Kersley J.H., Aslan P., Lynch W.B., and Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 172 (2004) 529-532
15. Melton III L.J., Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., and Zincke H. Fracture risk following bilateral orchiectomy. J Urol 169 (2003) 1747-1750
16. Krupski T.L., Smith M.R., Lee W.C., Pashos C.L., Brandman J., Wang Q., et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101 (2004) 541-549
17. Nguyen T.V., Eisman J.A., Kelly P.J., and Sambrook P.N. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144 (1996) 255-263
18. Greenspan S.L., Myers E.R., Maitland L.A., Resnick N.M., and Hayes W.C. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 271 (1994) 128-133
19. Nguyen T., Sambrook P., Kelly P., Jones G., Lord S., Freund J., et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 307 (1993) 1111-1115
20. Jones G., Nguyen T., Sambrook P.N., Kelly P.J., Gilbert C., and Eisman J.A. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4 (1994) 277-282
21. Nguyen T.V., Sambrook P.N., and Eisman J.A. Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss. J Bone Miner Res 12 (1997) 124-135
22. Lord S.R., Clark R.D., and Webster I.W. Postural stability and associated physiological factors in a population of aged persons. J Gerontol 46 (1991) M69-M76
23. Cox D.R. Regression models and life tables. J R Stat Soc (B) 34 (1972) 187-220
24. Lee E.T. Statistical models for survival data analysis (1980), Lifetime Learning Publications, Belmont, CA
25. Grambsch P.M., and Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
26. SAS Institute Inc. Base SAS 9.1.3 Procedures Guide vol. 1-4 (2004), SAS Publishing, Base SAS. Cary, NC, USA
27. R Development Core Team R. A language and environment for statistical computing (2008), R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org URL:http://www.R-project.org
28. Smith M.R., McGovern F.J., Fallon M.A., Schoenfeld D., Kantoff P.W., and Finkelstein J.S. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 (2001) 2238-2245
29. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
30. Travis R.C., Key T.J., Allen N.E., Appleby P.N., Roddam A.W., Rinaldi S., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121 (2007) 1331-1338
31. Chen C., Weiss N.S., Stanczyk F.Z., Lewis S.K., DiTommaso D., Etzioni R., et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 12 (2003) 1410-1416
32. Stattin P., Lumme S., Tenkanen L., Alfthan H., Jellum E., Hallmans G., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108 (2004) 418-424
33. Parsons J.K., Carter H.B., Platz E.A., Wright E.J., Landis P., and Metter E.J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14 (2005) 2257-2260
34. Severi G., Morris H.A., MacInnis R.J., English D.R., Tilley W., Hopper J.L., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 86-91
35. Platz E.A., Leitzmann M.F., Rifai N., Kantoff P.W., Chen Y.C., Stampfer M.J., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 (2005) 1262-1269
36. Weiss J.M., Huang W.Y., Rinaldi S., Fears T.R., Chatterjee N., Hsing A.W., et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Online Publication. Int J Cancer 122 10 (2008) 2345-2350
37. Meier C., Nguyen T.V., Handelsman D.J., Schindler C., Kushnir M.M., Rockwood A.L., et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168 (2008) 47-54
38. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocr Rev 25 (2004) 389-425
39. Berruti A., Dogliotti L., Tucci M., Tarabuzzi R., Fontana D., and Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 166 (2001) 2023-2031
40. Jones G., Nguyen T., Sambrook P.N., Kelly P.J., and Eisman J.A. A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol 22 (1995) 932-936